Duration of immunity to norovirus gastroenteritis

Emerging Infectious Diseases

Volumn 19, Issue 8, 2013, Pages 1260-1267

  Simmons, Kirsten ^a,b   Gambhir, Manoj ^a,c   Leon, Juan ^a   Lopman, Ben ^a,b  

^a EMORY UNIVERSITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; ASYMPTOMATIC DISEASE; BASIC REPRODUCTION NUMBER; CHILD; GASTROENTERITIS; GENETIC RESISTANCE; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNITY; INCUBATION TIME; INFANT; LIFE EXPECTANCY; MATHEMATICAL MODEL; NEWBORN; NOROVIRUS; PRESCHOOL CHILD; SEASONAL VARIATION; VIRUS TRANSMISSION;

ACUTE GASTROENTERITIS; ENTERIC INFECTIONS; IMMUNITY; INCIDENCE; MATHEMATICAL MODEL; MODELING; NOROVIRUS; VACCINATION; VACCINE DEVELOPMENT; VIRUSES;

ADOLESCENT; ADULT; AGE FACTORS; ALGORITHMS; CALICIVIRIDAE INFECTIONS; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DISEASE OUTBREAKS; GASTROENTERITIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, ACTIVE; INCIDENCE; INFANT; MODELS, IMMUNOLOGICAL; NOROVIRUS; POISSON DISTRIBUTION; UNITED STATES; VACCINATION; VIRAL VACCINES; YOUNG ADULT;

EID: 84880704577     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1908.130472     Document Type: Article

References (41)

1. Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM. Foodborne illness acquired in the United States-unspecified agents. Emerg Infect Dis. 2011;17:16-22. http://dx.doi.org/10.3201/eid1701.P21101
2. Hall AJ, Rosenthal M, Gregoricus N, Greene SA, Ferguson J, Henao OL, et al. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004-2005. Emerg Infect Dis. 2011;17:1381-1388.
3. Lopman B, Gastañaduy P, Park GW, Hall AJ, Parashar UD, Vinjé J. Environmental transmission of norovirus gastroenteritis. Curr Opin Virol. 2012;2:96-102. http://dx.doi.org/10.1016/j.coviro.2011.11.005
4. Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis- associated deaths in the United States, 1999-2007. Clin Infect Dis. 2012;55:216-223. http://dx.doi.org/10.1093/cid/cis386
5. Phillips G, Tam CC, Conti S, Rodrigues LC, Brown D, Iturriza-Gomara M, et al. Community incidence of norovirus-associated infectious intestinal disease in England: improved estimates using viral load for norovirus diagnosis. Am J Epidemiol. 2010;171:1014-1022. http://dx.doi.org/10.1093/aje/kwq021
6. Parker SP, Cubitt WD, Jiang XJ, Estes MK. Seroprevalence studies using a recombinant Norwalk virus protein enzyme immunoassay. J Med Virol. 1994;42:146-50. http://dx.doi.org/10.1002/jmv.1890420209
7. Jing Y, Qian Y, Huo Y, Wang LP, Jiang X. Seroprevalence against Norwalk-like human caliciviruses in Beijing, China. J Med Virol. 2000;60:97-101. http://dx.doi.org/10.1002/(SICI)1096-9071(200001)60:197:AID-JMV163.0.CO;2-D
8. Parrino TA, Schreiber D, Trier J, Kapikian A, Blacklow N. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med. 1977;297:86-9. http://dx.doi.org/10.1056/NEJM197707142970204
9. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiplechallenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis. 1990;161:18-21, ONUDL 2153184.
10. Dolin R, Blacklow NR, DuPont H, Formal S, Buscho RF, Kasel J. Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. J Infect Dis. 1971;123:307-12. http://dx.doi.org/10.1093/infdis/123.3.307
11. Wyatt RG, Dolin R, Blacklow NR, DuPont HL, Buscho RF, Thornhill TS, et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis. 1974;129:709-14. http://dx.doi.org/10.1093/infdis/129.6.709
12. Graham DY, Jiang X, Tanaka T, Opekun AR, Madore HP, Estes MK. Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis. 1994;170:34-43. http://dx.doi.org/10.1093/infdis/170.1.34
13. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis. 2010;202:1212-1218. http://dx.doi.org/10.1086/656364
14. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med. 2011;365:2178-2187. http://dx.doi.org/10.1056/NEJMoa1101245
15. Le Pendu J, Ruvo N, Kindberg E, Svensson L. Mendelian resistance to human norovirus infections. Semin Immunol. 2006;18:375-386. http://dx.doi.org/10.1016/j.smim.2006.07.009
16. Teunis PFM, Moe CL, Liu P, Miller SE, Lindesmith L, Baric RS, et al. Norwalk virus: how infectious is it? J Med Virol. 2008;80:1468-1476. http://dx.doi.org/10.1002/jmv.21237
17. Johnson PC, Mathewson JJ, Dupont HL, Greenberg HB. Study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis. 1990;161:18-21. http://dx.doi.org/10.1093/infdis/161.1.18
18. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003;9:548-53. http://dx.doi.org/10.1038/nm860
19. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol. 2005;79:2900-2909. http://dx.doi.org/10.1128/JVI.79.5.2900-2909.2005
20. Atmar RL, Opekun AR. Gilger MA, Estes MK, Crawford SE, Neill FH, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis. 2008;14:1553-7.
21. Leon JS, Kingsley DH, Montes JS, Richards GP, Lyon GM, Abdulhafid GM, et al. Randomized, double-blinded clinical trial for human norovirus inactivation in oysters by high hydrostatic pressure processing. Appl Environ Microbiol. 2011;77:5476-82. http://dx.doi.org/10.1128/AEM.02801-10
22. Seitz SR, Leon JS, Schwab KJ, Lyon GM, Dowd M, McDaniels M, et al. Norovirus infectivity in humans and persistence in water. Appl Environ Microbiol. 2011;77:6884-8. http://dx.doi.org/10.1128/AEM.05806-11
23. Frenck R, Bernstein DI, Xia M, Huang P, Zhong W, Parker S, et al. Predicting susceptibility to norovirus GII. 4 by use of a challenge model involving humans. J Infect Dis. 2012;206:1386-93. http://dx.doi.org/10.1093/infdis/jis514
24. Centers for Disease Control and Prevention. FastStats-Life expectancy [cited 2012 Sep 13]. http://www.cdc.gov/nchs/fastats/lifexpec.htm
25. Rockx B, De Wit M, Vennema H, Vinjé J, De Bruin E, Van Duynhoven Y, et al. Natural history of human calicivirus infection: a prospective cohort study. Clin Infect Dis. 2002;35:246-253. http://dx.doi.org/10.1086/341408
26. Sukhrie FHA, Siebenga JJ, Beersma MFC, Koopmans M. Chronic shedders as reservoir for nosocomial transmission of norovirus. J Clin Microbiol. 2010;48:4303-4325. http://dx.doi.org/10.1128/JCM.01308-10
27. Rosenthal NA, Lee LE, Vermeulen BAJ, Hedberg K, Keene WE, Widdowson M-A, et al. Epidemiological and genetic characteristics of norovirus outbreaks in long-term care facilities, 2003-2006. Epidemiol Infect. 2011;139:286-294. http://dx.doi.org/10.1017/S095026881000083X
28. Ozawa K, Oka T, Takeda N, Hansman GS. Norovirus infections in symptomatic and asymptomatic food-handlers in Japan. J Clin Microbiol. 2007;45:3996-4005. http://dx.doi.org/10.1128/JCM.01516-07
29. Sukhrie FHA, Teunis P, Vennema H, Copra C, Beersma MFCT, Bogerman J, et al. Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin Infect Dis. 2012;54:931-937. http://dx.doi.org/10.1093/cid/cir971
30. de Wit MAS, Koopmans MP, Kortbeek LM, Wannet WJ, Vinjé J, Van Leusden F, et al. Sensor, a population-based cohort study on gastroenteritis in the Netherlands: incidence and etiology. Am J Epidemiol. 2001;154:666-74. http://dx.doi.org/10.1093/aje/154.7.666
31. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases [cited 2012 Jul 13]. PLoS Med. 2008;5:e74. http://dx.doi.org/10.1371/journal.pmed.0050074
32. Vega E, Barclay L, Gregoricus N, Williams K, Lee D, et al. Novel surveillance network for norovirus gastroenteritis. Emerg Infect Dis. 2011;17:1389-1395.
33. Siebenga JJ, Vennema H, Zheng D-P, Vinjé J, Lee BE, Pang X-L, et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J Infect Dis. 2009;200:802-812. http://dx.doi.org/10.1086/605127
34. White LJ, Mandl JN, Gomes MGM, Bodley-Tickell AT, Cane PA, Perez-Brena P, et al. Understanding the transmission dynamics of respiratory syncytial virus using multiple time series and nested models. Math Biosci. 2007;209:222-239. http://dx.doi.org/10.1016/j.mbs.2006.08.018
35. Yen C, Wikswo ME. Lopman BA, Vinje J, Parashar UD, Hall AJ. Impact of an emergent norovirus variant in 2009 on norovirus outbreak activity in the United States. Clin Infect Dis. 2011;53:568-571. http://dx.doi.org/10.1093/cid/cir478
36. Thomas-Crusells J, McElhaney JE, Aguado MT. Report of the ad-hoc consultation on aging and immunization for a future WHO research agenda on life-course immunization. Vaccine. 2012;30:6007-12. http://dx.doi.org/10.1016/j.vaccine.2012.07.025
37. National Institutes of Health. ClinicalTrials.gov. Bivalent norovirus vaccine study [cited 2012 Sep 11]. http://clinicaltrials.gov/ct2/show/NCT01168401?term=norovirus+ligocyte&rank=2
38. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med. 2008;359:1555-1564. http://dx.doi.org/10.1056/NEJMoa0708630
39. Tamma PD, Ault KA, Rio C, Steinhoff MC, Halsey NA, Omer SB. Reviews Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2009;201:547-552. http://dx.doi.org/10.1016/j.ajog.2009.09.034
40. Steinhoff MC, Omer SB. Influenza immunization in pregnancy: antibody responses in mothers and infants. N Engl J Med. 2010;362:1644-1646. http://dx.doi.org/10.1056/NEJMc0912599
41. Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine. 2012;30:7097-7104. http://dx.doi.org/10.1016/j.vaccine.2012.09.040